Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil
Authors:
- Carlos Henrique CamargoCarlos Henrique Camargo
- Amanda Yaeko YamadaAYAmanda Yaeko Yamada
- Andreia Rodrigues de SouzaASAndreia Rodrigues de Souza
- Marisa de Jesus de Castro LimaMLMarisa de Jesus de Castro Lima
- Marcos Paulo Vieira CunhaMarcos Paulo Vieira Cunha
- Pedro Smith Pereira FerraroPFPedro Smith Pereira Ferraro
- Claudio Tavares SacchiCSClaudio Tavares Sacchi
- Marlon Benedito Nascimento dos SantosMSMarlon Benedito Nascimento dos Santos
- Karoline Rodrigues CamposKCKaroline Rodrigues Campos
- Monique Ribeiro Tiba-CasasMTMonique Ribeiro Tiba-Casas
- Maristela Pinheiro FreireMFMaristela Pinheiro Freire
- Pasqual BarrettiPBPasqual Barretti
Open Access
Abstract
Pseudomonas aeruginosa, an opportunistic pathogen causing infections in immunocompromised patients, usually shows pronounced antimicrobial resistance. In recent years, the frequency of carbapenemases in P. aeruginosa has decreased, which allows use of new beta-lactams/combinations in antimicrobial therapy. Therefore, the in vitro evaluation of these drugs in contemporary isolates is warranted. We evaluated the antimicrobial susceptibility and genomic aspects of 119 clinical P. aeruginosa isolates from 24 different hospitals in Brazil in 2021–2022. Identification was performed via MALDI-TOF-MS, and antimicrobial susceptibility was identified through broth microdilution, gradient tests, or disk diffusion. Whole-genome sequencing was carried out using NextSeq equipment. The most active drug was cefiderocol (100%), followed by ceftazidime–avibactam (94.1%), ceftolozane–tazobactam (92.4%), and imipenem–relebactam (81.5%). Imipenem susceptibility was detected in 59 isolates (49.6%), and the most active aminoglycoside was tobramycin, to which 99 (83.2%) isolates were susceptible. Seventy-one different sequence types (STs) were detected, including twelve new STs described herein. The acquired resistance genes blaCTX-M-2 and blaKPC-2 were identified in ten (8.4%) and two (1.7%) isolates, respectively. Several virulence genes (exoSTUY, toxA, aprA, lasA/B, plcH) were also identified. We found that new antimicrobials are effective against the diverse P. aeruginosa population that has been circulating in Brazilian hospitals in recent years.Keywords
Funding Information
- Pfizer/Wyeth (2023/08958-0, 2019/21361-8, 2017/50333-7, 2018/21192-9, CNPq 302543/2021-0, CNPq 402158/2021-0)
- São Paulo Research Foundation (2023/08958-0, 2019/21361-8, 2017/50333-7, 2018/21192-9, CNPq 302543/2021-0, CNPq 402158/2021-0)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (2023/08958-0, 2019/21361-8, 2017/50333-7, 2018/21192-9, CNPq 302543/2021-0, CNPq 402158/2021-0)
This publication has 38 references indexed in Scilit:
- First clonal spread of KPC-producing Pseudomonas aeruginosa in Buenos Aires, ArgentinaInfection, Genetics and Evolution, 2012
- Pseudomonasgenomes: diverse and adaptableFEMS Microbiology Reviews, 2011
- SPM-1-Producing Pseudomonas aeruginosa : Analysis of the Ancestor Relationship Using Multilocus Sequence Typing, Pulsed-Field Gel Electrophoresis, and Automated RibotypingMicrobial Drug Resistance, 2011
- The Challenges of Antimicrobial Resistance in BrazilClinical Infectious Diseases, 2011
- Emergence of KPC-Producing Pseudomonas aeruginosa in the United StatesAntimicrobial Agents and Chemotherapy, 2010
- The Colistin-Only-Sensitive Brazilian Pseudomonas aeruginosa Clone SP (Sequence Type 277) Is Spread WorldwideAntimicrobial Agents and Chemotherapy, 2010
- Antibacterial-ResistantPseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance MechanismsClinical Microbiology Reviews, 2009
- The type III secretion system of Pseudomonas aeruginosa: infection by injectionNature Reviews Microbiology, 2009
- VFDB: a reference database for bacterial virulence factorsNucleic Acids Research, 2004
- Development of a Multilocus Sequence Typing Scheme for the Opportunistic Pathogen Pseudomonas aeruginosaJournal of Clinical Microbiology, 2004